

Preliminary agenda:

Biosimilars Explained: What Patients Need To

Know

Webinar | 13th October 2020 | 15:00 - 16:00

Chair: Antonella Cardone, ECPC Director

15:00 – 15:10 Welcome and Introduction
 Presentation of biosimilars e-learning module
 Antonella Cardone, ECPC Director

15:10 – 15:40 What are biosimilars and what is their meaning for patients
 Prof. Arnold Vulto, Erasmus University Medical Center in Rotterdam

15:40 – 15:50 Patient's video experience
15:50 – 16:00 Q&A



European Cancer Patient Coalition

www.ecpc.org info@ecpc.org 40, rue de Montoyer/Montoyerstraat B-1000 – Brussels (Belgium)



INFORMATION ABOUT OUR SPEAKERS

Antonella Cardone, Director of European Cancer Patient Coalition (ECPC)

Antonella Cardone is the Director of the European Cancer Patient Coalition, which is the largest cancer patient umbrella organization in Europe with over 450 members from 49 countries. She has over twenty years of international activity in health, social and employment sectors.

Prior to ECPC, Antonella was the Executive Director of the Fit for Work Global Alliance, a multi-stakeholder coalition championing change in health and work policy. She was previously Director of the Global Smokefree Partnership of the American Cancer Society, leading a movement of over 100 members to coordinate the development of smokefree laws in 40 countries. She holds a Master's in Science and one in Business Administration. She currently represents ECPC on the Board of Pancreatic Cancer Europe.





European Cancer Patient Coalition

www.ecpc.org info@ecpc.org 40, rue de Montoyer/Montoyerstraat B-1000 – Brussels (Belgium)



Prof. Arnold G. Vulto

Arnold G. Vulto is honorary professor of Hospital Pharmacy & Practical Therapeutics of the Hospital Pharmacy at Erasmus Medical Center in Rotterdam, The Netherlands. He obtained his pharmacy degree at Groningen University (the Netherlands), before completing postgraduate training at the Rudolf Magnus Institute for Pharmacology, University of Utrecht (the Netherlands) and at the Karolinska Institute, Stockholm (Sweden).

He joined the Erasmus Medical Center in 1995, where he became the professor of Hospital Pharmacy in 2004. Professor Vulto is a founding member of the MABEL Fund (Market Analysis of Biologics and Biosimilars following Loss of Exclusivity) which is a collaboration between Erasmus Medical Center and the Department of Clinical Pharmacology and Pharmacotherapy at the Catholic University of Leuven, Belgium. In 2017 he was appointed as Honorary Professor at the University of Leuven. He has been a member of the Board of Directors of the European Association of Hospital Pharmacists (EAHP) and was Chairman of the EAHP Scientific Committee from 2003–2006. In 2018 he was bestowed Officer in the Order of Orange-Nassau.

Professor Vulto was Editor-in-Chief of the European Journal of Hospital Pharmacy Practice (2005-2012) and has authored or co-authored more than 150 articles in international peerreviewed journals. Professor Vulto is one of the co-founders of the Generics and Biosimilars Initiative (GaBI) and also from Biosimilars the Netherlands, from which he is the chairman.





European Cancer Patient Coalition

www.ecpc.org info@ecpc.org 40, rue de Montoyer/Montoyerstraat B-1000 - Brussels (Belgium)